We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Touchlight announced an agreement with University of Liverpool for the use of dbDNA in the development of a fully-personalised therapeuticneoantigen DNA vaccine for patients with non-small cell lung cancer.